期刊文献+

四川地区血站分离血浆HIV/HBV/HCV残余风险研究 被引量:5

Evaluation of residual risk of HIV,HBV and HCV in recovered plasma in Sichuan Province
下载PDF
导出
摘要 目的评估四川地区血站分离血浆中HIV、HBV、HCV的残余风险。方法收集2013年1-12月四川9家血站HBs Ag、抗-HCV、抗-HIV筛查阳性样本,对筛查HBs Ag阳性标本采用中和试验确证,对筛查抗-HCV及抗-HIV阳性标本采用免疫印迹法确证。采用改良的发病率-窗口期模型计算HBV,HCV,HIV残余风险。结果四川地区血站分离血浆中HBV,HCV和HIV的残余风险分别为1/1 355,1/35 587和1/92 593。结论血站分离血浆仍存在一定残余风险,增加核酸检测等新型检测技术可进一步降低其残余风险。 Objective To evaluate the residual risks of HIV,HBV and HCV in recovered plasma in blood centers of China. Methods Samples which were screened reactive for HBs Ag,anti-HCV and anti-HIV were collected from nine blood centers in Sichuan,and then were subjected to confirmatory testing and neutralization assay for HBs Ag,RIBA for HCV and Wester-blot for HIV. The residual risk of HBV,HCV and HIV were calculated by a modified incidence-window model. Results The residual risks of HBV,HCV and HIV in blood centers of Sichuan province were 1 /1 355,1 /35 587,and1 /92 593,respectively. Conclusion The residual risks of recovered plasma still exist and more measures should be taken to reduce the risk of transfusion-transmitted infection diseases,such as the application of nucleic acid testing.
出处 《中国输血杂志》 CAS 北大核心 2015年第4期420-423,共4页 Chinese Journal of Blood Transfusion
关键词 HBV HCV HIV 残余风险 分离血浆 HBV HCV HIV residual risk recovered plasma
  • 相关文献

参考文献5

二级参考文献82

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 2王迅.核酸检测技术(NAT)及其在血液筛检中的应用[J].中国输血杂志,2004,17(6):465-468. 被引量:30
  • 3Swati Gupta,Sarman Singh.Hepatitis B and C virus co-infections in human immunodeficiency virus positive North Indian patients[J].World Journal of Gastroenterology,2006,12(42):6879-6883. 被引量:7
  • 4Holland PV. Post-transfusion hepatitis: current risks and causes. Vox Sang, 1998,74 Suppl 2:S135-141. 被引量:1
  • 5Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion, 2002,42(8) :975-979. 被引量:1
  • 6Soldan K, Barbara JAJ, Ramsay ME, et al. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001. Vox Sang, 2003,84 (4) : 274-286. 被引量:1
  • 7Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immtmodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion, 2010, 50 (7) : 1495-1504. 被引量:1
  • 8Gallarda JL, Dragon E. Blood screening by nucleic acid amplification technology : current issues, future challenges. Mol Diag, 2000, 5 (1):11-22. 被引量:1
  • 9Seed CR, Cheng A, Ismay SL, et al. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion, 2002,42 (10) : 1365-1372. 被引量:1
  • 10AuBuchon JP, Birkmeyer JD, Busch ME Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med, 1997, 127(10) : 904-909. 被引量:1

共引文献90

同被引文献43

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部